Cytokinetics (CYTK) Tops Q4 EPS Views; Offers FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Cytokinetics (CYTK) Surpasses FY14 Estimates Following Recent Astellas Deal; Roth Cap. Affirms at 'Buy'
February 13, 2015 8:29 AM ESTRoth Capital comments on Cytokinetics (Nasdaq: CYTK) following Q4, FY14 results reported late Thursday. The firm retains a Buy rating and $18 price target on Cytokinetics following the numbers and update.
Analyst Joseph Pantginis noted that Cytokinetics reported FY14 loss of $0.41 per share with revenue of $46.9 million, versus the firm's... More
Piper Jaffray Upgrades Cytokinetics (CYTK) to Overweight; Sees 100% Upside
February 13, 2015 6:46 AM ESTPiper Jaffray upgraded Cytokinetics (NASDAQ: CYTK) from Neutral to Overweight with a price target of $13.00 (from $7.00), suggesting 100% upside from current levels.
Analyst Charles Duncan commented, "Cytokinetics reported 4Q/FY14 results yesterday, ending '14 with $83M in cash which combined with inflows already in '15... More
